Top

Published in:

01-09-2008 | Original Article

Surgical Management of Gastroesophageal Reflux Disease in Obesity

Author: Sayeed Ikramuddin

Published in: Digestive Diseases and Sciences | Issue 9/2008

Abstract

Bariatric surgery is ubiquitous today. In the obese patient with comorbid gastroesophageal reflux disease (GERD), it is increasingly being used as an alternative to fundoplication because it not only has an effect on GERD but also on other comorbid illnesses. Traditional GERD surgery is designed to augment the mechanical barriers against reflux, decrease acid production in the stomach, improve gastric emptying, or divert bile from the stomach. Roux-en-Y gastric bypass addresses these issues in addition to resulting in profound weight loss in patients. Banding may have a positive influence in patients’ GERD, though to a lesser extent. The duodenal switch provides excellent control for patients with alkaline reflux. A revision of the 1991 National Institutes of Health guidelines for determining bariatric surgical candidates is overdue, and it may be feasible to consider expanding the body mass index and comorbidity requirements to reflect the benefits offered by these techniques for GERD patients.

Scherer PE (2006) Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55:1537–1545. doi:10.2337/db06-0263 PubMedCrossRef

Greenberg AS, Obin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83:461S–465SPubMed

Housa D, Housová J, Vernerová Z, Haluzík M (2006) Adipocytokines and cancer. Physiol Res 55:233–244PubMed

Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD (2002) Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev 3:9–15. doi:10.1046/j.1467-789X.2002.00049.x PubMedCrossRef

Mercer CD, Wren SF, DaCosta LR, Beck IT (1987) Lower esophageal sphincter pressure and gastroesophageal pressure gradients in excessively obese patients. J Med 18:135–146PubMed

Wajed SA, Streets CG, Bremner CG, DeMeester TR (2001) Elevated body mass disrupts the barrier to gastroesophageal reflux. Arch Surg 136:1014–1018. doi:10.1001/archsurg.136.9.1014 PubMedCrossRef

Kahrilas PJ, Pandolfino JE (2002) Gastroesophageal reflux disease and its complications, including Barrett’s metaplasia. In: Feldman M, Friedman LS, Sleisenger MH (eds) Gastrointestinal and liver disease: pathophysiology/diagnosis/management, 7th edn. Saunders, Philadelphia, pp 599–622

DeVault KR, Castell DO (2005) American College of Gastroenterology: updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100:190–200. doi:10.1111/j.1572-0241.2005.41217.x PubMedCrossRef

DeMeester TR, Fuchs KH, Ball CS, Albertucci M, Smyrk TC, Marcus JN (1987) Experimental and clinical results with proximal end-to-end duodenojejunostomy for pathologic duodenogastric reflux. Ann Surg 206:414–426. doi:10.1097/00000658-198710000-00003 PubMedCrossRef

10.

Vakil N (2007) The role of surgery in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 25:1365–1372PubMed

11.

Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F et al (2001) Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285:2331–2338. doi:10.1001/jama.285.18.2331 PubMedCrossRef

12.

Vakil N, Kirby R, Shaw M (2003) Clinical effectiveness of laparoscopic fundoplication in a US community. Am J Med 114:1–5. doi:10.1016/S0002-9343(02)01390-6 PubMedCrossRef

13.

Dominitz JA, Dire CA, Billingsley KG, Todd-Stenberg JA (2006) Complications and antireflux medication use after antireflux surgery. Clin Gastroenterol Hepatol 4:299–305. doi:10.1016/j.cgh.2005.12.019 PubMedCrossRef

14.

Madan A, Minocha A (2006) Despite high satisfaction, majority of gastro-oesophageal reflux disease patients continue to use proton pump inhibitors after antireflux surgery. Aliment Pharmacol Ther 23:601–605. doi:10.1111/j.1365-2036.2006.02788.x PubMedCrossRef

15.

Klaus A, Hinder RA, DeVault KR, Achem SR (2003) Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course. Am J Med 114:6–9. doi:10.1016/S0002-9343(02)01301-3 PubMedCrossRef

16.

Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Malm A et al (2007) Nordic GORD study group: seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Br J Surg 94:198–203. doi:10.1002/bjs.5492 PubMedCrossRef

17.

Mehta S, Bennett J, Mahon D, Rhodes M (2006) Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up. J Gastrointest Surg 10:1312–1316. doi:10.1016/j.gassur.2006.07.010 PubMedCrossRef

18.

Perez AR, Moncure AC, Rattner DW (2001) Obesity adversely affects the outcome of antireflux operations. Surg Endosc 15:986–989. doi:10.1007/s004640000392 PubMedCrossRef

19.

Morgenthal CB, Lin E, Shane MD, Hunter JG, Smith CD (2007) Who will fail laparoscopic Nissen fundoplication? Preoperative prediction of long-term outcomes. Surg Endosc 21:1978–1984. doi:10.1007/s00464-007-9490-7 PubMedCrossRef

20.

McNatt SS, Smith CD, Hunter JG et al (2000) Morbid obesity does not predict a poor outcome after laparoscopic antireflux surgery. Gastroenterology 118(suppl):SSAT A1033. Abstract 2260

21.

D’Alessio MJ, Arnaoutakis D, Giarelli N, Villadolid DV, Rosemurgy AS (2005) Obesity is not a contraindication to laparoscopic Nissen fundoplication. J Gastrointest Surg 9:949–954. doi:10.1016/j.gassur.2005.04.019 PubMedCrossRef

22.

National Institutes of Health (1992) Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 55(suppl 2):6155–6195

23.

Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724–1737. doi:10.1001/jama.292.14.1724 PubMedCrossRef

24.

Balsiger BM, Poggio JL, Mai J, Kelly KA, Sarr MG (2000) Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 4:598–605. doi:10.1016/S1091-255X(00)80108-0 PubMedCrossRef

25.

Ikramuddin S, Kendrick ML, Kellogg TA, Sarr MG (2007) Open and laparoscopic Roux-en-Y gastric bypass: our techniques. J Gastrointest Surg 11:217–228. doi:10.1007/s11605-006-0028-4

26.

Schneider BE, Villegas L, Blackburn GL, Mun EC, Critchlow JF, Jones DB (2003) Laparoscopic gastric bypass surgery: outcomes. J Laparoendosc Adv Surg Tech A 13:247–255. doi:10.1089/109264203322333575 PubMedCrossRef

27.

Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350. doi:10.1097/00000658-199509000-00011 PubMedCrossRef

28.

Buchwald H, Ikramuddin S (2002) Laparoscopic adjustable gastric banding in bariatric surgery: an overview of the LAP-BAND: introduction. Am J Surg 184:1S–3S. doi:10.1016/S0002-9610(02)01171-6 PubMedCrossRef

29.

Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J (2000) Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 232:515–529. doi:10.1097/00000658-200010000-00007 PubMedCrossRef

30.

Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G et al (2003) Effect of laparoscopic Roux-en Y bypass on type 2 diabetes mellitus. Ann Surg 238:467–484PubMed

31.

Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP et al (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630. doi:10.1056/NEJMoa012908 PubMedCrossRef

32.

Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ et al (2007) Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res 141:31–39. doi:10.1016/j.jss.2007.02.022 PubMedCrossRef

33.

Greenway SE, Greenway FL 3rd, Klein S (2002) Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 137:1109–1117. doi:10.1001/archsurg.137.10.1109 PubMedCrossRef

34.

Ballantyne GH (2006) Peptide YY(1-36) and peptide YY(3-36): part I. Distribution, release and actions. Obes Surg 16:651–658. doi:10.1381/096089206776944959 PubMedCrossRef

35.

Ballantyne GH (2006) Peptide YY(1-36) and peptide YY(3-36): part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 16:795–803. doi:10.1381/096089206777346619 PubMedCrossRef

36.

Ballantyne GH, Farkas D, Laker S, Wasielewski A (2006) Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass. Obes Surg 16:1189–1197. doi:10.1381/096089206778392158 PubMedCrossRef

37.

Rubino F, Marescaux J (2004) Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239:1–11. doi:10.1097/01.sla.0000102989.54824.fc PubMedCrossRef

38.

Mattar SG, Qureshi F, Taylor D, Schauer PR (2006) Treatment of refractory gastroesophageal reflux disease with radiofrequency energy (Stretta) in patients after Roux-en-Y gastric bypass. Surg Endosc 20:850–854. doi:10.1007/s00464-006-0513-6 PubMedCrossRef

39.

Smith CD, Herkes SB, Behrns KE, Fairbanks VF, Kelly KA, Sarr MG (1993) Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. Ann Surg 218:91–96. doi:10.1097/00000658-199307000-00014 PubMedCrossRef

40.

Johnson WH, Fernanadez AZ, Farrell TM, Macdonald KG, Grant JP, McMahon RL et al (2007) Surgical revision of loop (“mini”) gastric bypass procedure: multicenter review of complications and conversions to Roux-en-Y gastric bypass. Surg Obes Relat Dis 3:37–41. doi:10.1016/j.soard.2006.09.012 PubMedCrossRef

41.

Smith SC, Edwards CB, Goodman GN (1997) Symptomatic and clinical improvement in morbidly obese patients with gastroesophageal reflux disease following Roux-en-Y gastric bypass. Obes Surg 7:479–484. doi:10.1381/096089297765555205 PubMedCrossRef

42.

Jones KB Jr (1998) Roux-en-Y gastric bypass: an effective antireflux procedure in the less than morbidly obese. Obes Surg 8:35–38. doi:10.1381/096089298765555024 PubMedCrossRef

43.

Frezza EE, Ikramuddin S, Gourash W, Rakitt T, Kingston A, Luketich J et al (2002) Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc 16:1027–1031. doi:10.1007/s00464-001-8313-5 PubMedCrossRef

44.

Dixon JB, O’Brien PE (1999) Gastroesophageal reflux in obesity: the effect of lap-band placement. Obes Surg 9:527–531. doi:10.1381/096089299765552602 PubMedCrossRef

45.

Patterson EJ, Davis DG, Khajanchee Y, Swanström LL (2003) Comparison of objective outcomes following laparoscopic Nissen fundoplication versus laparoscopic gastric bypass in the morbidly obese with heartburn. Surg Endosc 17:1561–1565. doi:10.1007/s00464-002-8955-y PubMedCrossRef

46.

Ryden A, Torgerson JS (2006) The Swedish obese subjects study—what has been accomplished to date? Surg Obes Relat Dis 2:549–560. doi:10.1016/j.soard.2006.07.006 PubMedCrossRef

47.

Christou NV, Sampalis JS, Liberman M, Look D, Augur S, McLean AP et al (2004) Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 240:416–423. doi:10.1097/01.sla.0000137343.63376.19 PubMedCrossRef

48.

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wede IH et al (2007) Swedish obese subjects study: effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357:741–752. doi:10.1056/NEJMoa066254 PubMedCrossRef

49.

Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357:753–761. doi:10.1056/NEJMoa066603 PubMedCrossRef

50.

Horgan S, Pohl D, Bogetti D, Eubanks T, Pellegrini C (1999) Failed antireflux surgery: what have we learned from reoperations? Arch Surg 134:809–815. doi:10.1001/archsurg.134.8.809 PubMedCrossRef

51.

Soper NJ, Dunnegan D (1999) Anatomic fundoplication failure after laparoscopic antireflux surgery. Ann Surg 229:669–676. doi:10.1097/00000658-199905000-00009 PubMedCrossRef

52.

Wilson LJ, Ma W, Hirschowitz BI (1999) Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 94:2840–2844. doi:10.1111/j.1572-0241.1999.01426.x PubMedCrossRef

53.

Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ (2006) Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 130:639–649. doi:10.1053/j.gastro.2005.12.016 PubMedCrossRef

54.

Hunter JG, Smith CD, Branum GD, Waring JP, Trus TL, Cornwell M et al (1999) Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. Ann Surg 230:595–604. doi:10.1097/00000658-199910000-00015 PubMedCrossRef

55.

Kellogg TA, Andrade R, Maddaus M, Slusarek B, Buchwald H, Ikramuddin S (2007) Anatomic findings and outcomes after antireflux procedures in morbidly obese patients undergoing laparoscopic conversion to Roux-en-Y gastric bypass. Surg Obes Relat Dis 3:52–57. doi:10.1016/j.soard.2006.08.011 PubMedCrossRef

Title: Surgical Management of Gastroesophageal Reflux Disease in Obesity
Author: Sayeed Ikramuddin
Publication date: 01-09-2008
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 9/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0415-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2008

The Effect of Hiatal Hernia on Gastroesophageal Reflux Disease and Influence on Proximal and Distal Esophageal Reflux

The Association Between Obesity and GERD: A Review of the Epidemiological Evidence

Scoring System for Predicting Response to Chemoradiotherapy, Including 5-Fluorouracil and Platinum, for Patients with Esophageal Cancer

Body Mass Index and Gastroesophageal Reflux Disease: Implications of the Obesity Epidemic

Protective Effect of Octreotide and Infliximab in an Experimental Model of Indomethacin-Induced Inflammatory Bowel Disease

The Epidemiology of Obesity and Gastrointestinal and Other Diseases: An Overview

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage